May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Inhibition of Human Eosinophil Functions by Ketotifen in vitro
Author Affiliations & Notes
  • R. Lanz
    Novartis Ophthalmics, Basel/Bülach, Switzerland
  • G. Woerly
    Centre d'Immunologie et Biologie Parasitaire, Unité INSERM-IPL U547, Institut Pasteur, Lille, France
  • S. Loiseau
    Centre d'Immunologie et Biologie Parasitaire, Unité INSERM-IPL U547, Institut Pasteur, Lille, France
  • M. Loyens
    Centre d'Immunologie et Biologie Parasitaire, Unité INSERM-IPL U547, Institut Pasteur, Lille, France
  • C. Schoch
    Centre d'Immunologie et Biologie Parasitaire, Unité INSERM-IPL U547, Institut Pasteur, Lille, France
  • M. Capron
    Centre d'Immunologie et Biologie Parasitaire, Unité INSERM-IPL U547, Institut Pasteur, Lille, France
  • Footnotes
    Commercial Relationships  R. Lanz, Novartis Ophthalmics E; G. Woerly, Novartis Ophthalmics F; S. Loiseau, Novartis Ophthalmics F; M. Loyens, Novartis Ophthalmics F; C. Schoch, Novartis Ophthalmics E; M. Capron, Novartis Ophthalmics F.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 1294. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      R. Lanz, G. Woerly, S. Loiseau, M. Loyens, C. Schoch, M. Capron; Inhibition of Human Eosinophil Functions by Ketotifen in vitro . Invest. Ophthalmol. Vis. Sci. 2003;44(13):1294.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate the effects of ketotifen, a drug with multiple mechanisms of action used for the treatment of allergic conjunctivitis, on human eosinophil chemotaxis, oxidative metabolism, and mediator release induced after activation. Methods: Eosinophils from hypereosinophilic patients or normal donors were purified by Percoll gradient and isolated by immunomagnetic separation using the MACS system. Chemotaxis was studied in a Boyden chamber using three potent chemoattractants, fMLP, IL-5 and eotaxin. Oxidative metabolism was determined by a luminol-dependent chemiluminescence assay after activation with eotaxin or secretory IgA (sIgA). Release of eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) was measured by radioimmunoassay after activation with sIgA. Results: At therapeutically relevant concentrations (10-4–10-8 Mol/L), ketotifen inhibited chemotaxis of eosinophils to fMLP, IL-5 and eotaxin in a dose-dependent manner. Production of reactive oxygen species (ROS) induced by eotaxin and sIgA was significantly decreased by ketotifen, the effect being more pronounced when cells were activated by eotaxin. Activation by sIgA resulted in ECP and EDN release, which was partially inhibited by ketotifen. Conclusions: Through inhibition of chemotaxis, ketotifen has the potential to limit the number of eosinophils at the site of inflammation during the allergic reaction. Furthermore, inhibition of release of main inflammatory mediators suggests a possible role of ketotifen in limiting the pathological potential of eosinophils.

Keywords: conjunctivitis • cytokines/chemokines • pharmacology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×